Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy

Allergy ◽  
2015 ◽  
Vol 70 (6) ◽  
pp. 715-719 ◽  
Author(s):  
C. Möbs ◽  
J. Müller ◽  
A. Rudzio ◽  
J. Pickert ◽  
S. Blank ◽  
...  
Keyword(s):  
Allergen Immunotherapy ◽  
Wasp Venom ◽  
Ves V 5 ◽  
Blocking Capacity

scholarly journals Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy

Immunology ◽  
2003 ◽  
Vol 110 (3) ◽  
pp. 376-385 ◽  
Author(s):  
Birgit Winkler ◽  
Caroline Bolwig ◽  
Ulla Seppala ◽  
Michael D. Spangfort ◽  
Christof Ebner ◽  
...  
Keyword(s):  
Murine Model ◽  
Major Allergen ◽  
Venom Allergy ◽  
Wasp Venom ◽  
Vespula Vulgaris ◽  
Ves V 5 ◽  
Wasp Venom Allergy ◽  
Specific Immunosuppression

Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe

2012 ◽  
Vol 130 (3) ◽  
pp. 817 ◽  
Author(s):  
Gunter J. Sturm ◽  
Maria Beatrice Biló ◽  
Patrizia Bonadonna ◽  
Wolfgang Hemmer ◽  
Beatrice Caruso ◽  
...  
Keyword(s):  
Specific Ige ◽  
Wasp Venom ◽  
Ves V 5

Serum immunoglobulin E reactivity to cross-reacting panallergen components in north-eastern Poland patients pollen sensitized

2020 ◽  
Vol 41 (3) ◽  
pp. 183-191
Author(s):  
Krzysztof Kowal ◽  
Agnieszka Pampuch ◽  
Ewa Sacharzewska ◽  
Ewa Swiebocka ◽  
Zenon Siergiejko ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Immunoglobulin E ◽  
Pollen Allergy ◽  
Serum Ige ◽  
Ige Reactivity ◽  
Allergen Components ◽  
North Eastern ◽  
Allergen Sources ◽  
Seasonal Pollen

Background: The presence of immunoglobulin E (IgE), which cross-reacts with allergen components, such as profilins, polcalcins, and cross-reacting carbohydrate determinants (CCD), creates a problem when selecting patients for allergen immunotherapy by using conventional methods. The aim of this study was to evaluate the prevalence of sensitization to profilins, polcalcins, and CCDs in patients with seasonal pollen allergic rhinitis. Methods: The study was performed on a group of 112 patients with seasonal pollen allergic rhinitis, ages 14 to 55 years, with sensitization to at least one seasonal allergen (IgE > 0.7 kUA/L). The presence of IgE sensitization to recombinant (r) Bet v 2, rPhl p 12, rBet v 4, rPhl p 7, and CCDs, in addition to rBet v 1, rPhl p 1, rPhl p 5, was evaluated by using a multiparameter immunoblot. Results: Among the studied patients, 64.3, 80.4, and 41.1% were sensitized to birch, timothy grass, and mugwort pollen, respectively. Sensitization to profilins rBet v 2/Phl p 12 was demonstrated in 28.6%, to polcalcins Bet v 4/Phl p 7 in 8.9%, and to CCDs in 25%. In 29.3%, serum IgE reactivity to any of the cross-reactive components could be demonstrated. Serum IgE reactivity to rBet v 2 was always accompanied by IgE reactivity to rPhl p 12, and IgE reactivity to rBet v 4 was always accompanied by IgE reactivity to rPhl p 7. Among the patients with pollinosis co-sensitized to at least two allergen sources according to extract-based diagnosis, possible false-positive results due to sensitization to cross-reactive components were detected in 17.9%. Conclusion: Evaluation of sensitization to cross-reacting components may be useful in evaluation of patients with pollen allergy who are being assessed for allergen immunotherapy to optimize the constitution of their immunotherapy vaccines.

Sign in / Sign up

Export Citation Format

Share Document